Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings

作     者：Seng Gee Lim 

作者机构：Department of Gastroenterology and Hepa-tology Department of Medicine National University Health System Yong Loo Lin School of Medicine National University of Singapore 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第6期

页      面：1972-1981页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：Chronic hepatitis C hepatitis C virus RNA Sustaine 

摘      要：AIM:To use existing hepatitis C virus(HCV)antiviral therapies as access to new treatments is ***:A Pub Med search for randomised control trials or meta-analysis related to response-guided therapy of HCV genotype 1 patients was undertaken using pegylated interferon and ribavirin(PR),boceprevir(B)and telaprevir(T)and lead-in where responseguided therapy at TW4(TW4),8(TW8),10(TW10),or12(TW12)based on HCVRNA(+)or HCVRNA(-).Studies presented at major conferences were also *** necessary,a post-hoc analysis was performed.A response-guided management roadmap was created based on sustained virological response(SVR).RESULTS:Starting with PR,those with HCVRNA(-)at TW4 have86%SVR,while those are HCVRNA(+)have 34%-41.7%***(-)TW4 patients can have 24 wk PR if HCVRNA80%SVR,leading to the80-80***:Using a roadmap based on HCVRNA(-)at TW4 or TW8(the80-80rule),high SVR can be achieved,and guide the best choices for treatment,and also reduces drug exposure in poor responders.